Alex Brill Interviewed on Future of US Biosimilars Market
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts, such as a loss of innovation, reduced investment in the biosimilar market, and a lack of interest among drug companies to shell out the resources to develop new medications — essentially stifling competition and leading to long-term price increases.
Read the full article here (subscription required)
